S&P 500   4,272.48 (-0.36%)
DOW   33,344.84 (-0.49%)
QQQ   359.69 (+0.40%)
AAPL   173.39 (+1.27%)
MSFT   318.77 (+0.96%)
META   304.13 (+1.31%)
GOOGL   133.22 (+1.80%)
AMZN   128.85 (+1.36%)
TSLA   249.37 (-0.34%)
NVDA   447.92 (+2.97%)
NIO   8.75 (-3.21%)
BABA   86.24 (-0.58%)
AMD   102.92 (+0.10%)
T   14.78 (-1.60%)
F   12.27 (-1.21%)
MU   67.74 (-0.43%)
CGC   0.73 (-6.75%)
GE   108.81 (-1.57%)
DIS   81.36 (+0.38%)
AMC   7.96 (-0.38%)
PFE   33.66 (+1.48%)
PYPL   58.39 (-0.12%)
NFLX   379.15 (+0.41%)
S&P 500   4,272.48 (-0.36%)
DOW   33,344.84 (-0.49%)
QQQ   359.69 (+0.40%)
AAPL   173.39 (+1.27%)
MSFT   318.77 (+0.96%)
META   304.13 (+1.31%)
GOOGL   133.22 (+1.80%)
AMZN   128.85 (+1.36%)
TSLA   249.37 (-0.34%)
NVDA   447.92 (+2.97%)
NIO   8.75 (-3.21%)
BABA   86.24 (-0.58%)
AMD   102.92 (+0.10%)
T   14.78 (-1.60%)
F   12.27 (-1.21%)
MU   67.74 (-0.43%)
CGC   0.73 (-6.75%)
GE   108.81 (-1.57%)
DIS   81.36 (+0.38%)
AMC   7.96 (-0.38%)
PFE   33.66 (+1.48%)
PYPL   58.39 (-0.12%)
NFLX   379.15 (+0.41%)
S&P 500   4,272.48 (-0.36%)
DOW   33,344.84 (-0.49%)
QQQ   359.69 (+0.40%)
AAPL   173.39 (+1.27%)
MSFT   318.77 (+0.96%)
META   304.13 (+1.31%)
GOOGL   133.22 (+1.80%)
AMZN   128.85 (+1.36%)
TSLA   249.37 (-0.34%)
NVDA   447.92 (+2.97%)
NIO   8.75 (-3.21%)
BABA   86.24 (-0.58%)
AMD   102.92 (+0.10%)
T   14.78 (-1.60%)
F   12.27 (-1.21%)
MU   67.74 (-0.43%)
CGC   0.73 (-6.75%)
GE   108.81 (-1.57%)
DIS   81.36 (+0.38%)
AMC   7.96 (-0.38%)
PFE   33.66 (+1.48%)
PYPL   58.39 (-0.12%)
NFLX   379.15 (+0.41%)
S&P 500   4,272.48 (-0.36%)
DOW   33,344.84 (-0.49%)
QQQ   359.69 (+0.40%)
AAPL   173.39 (+1.27%)
MSFT   318.77 (+0.96%)
META   304.13 (+1.31%)
GOOGL   133.22 (+1.80%)
AMZN   128.85 (+1.36%)
TSLA   249.37 (-0.34%)
NVDA   447.92 (+2.97%)
NIO   8.75 (-3.21%)
BABA   86.24 (-0.58%)
AMD   102.92 (+0.10%)
T   14.78 (-1.60%)
F   12.27 (-1.21%)
MU   67.74 (-0.43%)
CGC   0.73 (-6.75%)
GE   108.81 (-1.57%)
DIS   81.36 (+0.38%)
AMC   7.96 (-0.38%)
PFE   33.66 (+1.48%)
PYPL   58.39 (-0.12%)
NFLX   379.15 (+0.41%)
OTCMKTS:ATBPF

Antibe Therapeutics (ATBPF) Stock Forecast, Price & News

$0.36
0.00 (0.00%)
(As of 09/29/2023 ET)
Compare
Today's Range
$0.36
$0.36
50-Day Range
$0.34
$0.43
52-Week Range
$0.28
$0.53
Volume
N/A
Average Volume
10,688 shs
Market Capitalization
$18.86 million
P/E Ratio
N/A
Dividend Yield
N/A
Price Target
N/A

ATBPF stock logo

About Antibe Therapeutics (OTCMKTS:ATBPF) Stock

Antibe Therapeutics Inc., a biotechnology company, engages in developing novel therapeutics and medical devices in the areas of pain, inflammation and regenerative medicine in Canada, Europe, the United States, and internationally. The company's pipeline includes therapies that seek to overcome the gastrointestinal (GI) ulcers and bleeding associated with nonsteroidal anti-inflammatory drugs (NSAIDs). Its lead compound is Otenaproxesul, an NSAID that releases hydrogen sulfide for treating post-operative pain, migraine, acute musculoskeletal pain, dysmenorrhea, gout, and dental pain. In addition, its products comprise ATB-352, which is in preclinical stage for acute pain. The company was incorporated in 2009 and is headquartered in Toronto, Canada.

ATBPF Price History

ATBPF Stock News Headlines

Antibe Announces Results of 2023 Annual Meeting
[BREAKING] Small Firm Wins $1 Billion Army Contract for Breakthrough "Living Software"
The Washington Post Reports it's: "A revolution in warfare." The Sunday Times Reports it's: "a revolutionary power." Early investors can reap 5,633% gains as England, Germany, Japan and Australia rush to sign contracts. Get the name of the stock here >>>
Antibe Therapeutics Inc. (ATBPF)
Maxim Group Reaffirms Their Buy Rating on Antibe Therapeutics (ATBPF)
Watch SHOCKING Footage of AI Facility with Ties to Elon Musk
I recently traveled more than 3,000 miles and shot this video outside what could end up being Elon Musk’s biggest secret. Most people don’t know about this facility, but it could be the most important AI project in the world. What’s happening inside these walls is so important that our government has declared it a matter of national security.
Antibe Provides Development Update for Otenaproxesul
Antibe Announces Results of 2022 Annual Meeting
Antibe Therapeutics GAAP EPS of -$0.09
ATBPF Real-Time Quotes
See More Headlines
Receive ATBPF Stock News and Ratings via Email

Sign-up to receive the latest news and ratings for Antibe Therapeutics and its competitors with MarketBeat's FREE daily newsletter.

ATBPF Company Calendar

Last Earnings
8/14/2023
Today
10/02/2023
Next Earnings (Estimated)
11/13/2023
Fiscal Year End
3/31/2024

Industry, Sector and Symbol

Industry
Pharmaceutical preparations
Sub-Industry
N/A
Sector
Medical
Current Symbol
OTCMKTS:ATBPF
CIK
N/A
Fax
N/A
Employees
11
Year Founded
N/A

Profitability

Net Income
$-14,730,000.00
Pretax Margin
N/A

Debt

Sales & Book Value

Annual Sales
$7.67 million
Book Value
$0.58 per share

Miscellaneous

Free Float
47,900,000
Market Cap
$18.86 million
Optionable
Not Optionable
Beta
0.36
The Best High-Yield Dividend Stocks for 2023 Cover

Looking to generate income with your stock portfolio? Use these ten stocks to generate a safe and reliable source of investment income.

Get This Free Report

Key Executives

  • Mr. Daniel Marcel Legault J.D. (Age 65)
    L.L.B., Pres, CEO, Sec. & Director
    Comp: $549.34k
  • Mr. Alain Wilson M.B.A.
    MBA, Chief Financial Officer
  • Mr. Scott Curtis C.F.A.
    M.Eng, Chief Operating Officer
  • Dr. David James Vaughan Ph.D. (Age 73)
    Chief Devel. Officer
    Comp: $299.94k
  • Dr. Joseph Stauffer D.O. (Age 57)
    M.B.A., Chief Medical Officer
    Comp: $818.8k
  • Dr. Ana Stegic
    Exec. Director of Clinical Operations
  • Ms. Christina Cameron B.B.A.
    VP of Investor Relations
  • Mr. Philip Stern
    VP of Communications













ATBPF Stock - Frequently Asked Questions

Should I buy or sell Antibe Therapeutics stock right now?

1 Wall Street equities research analysts have issued "buy," "hold," and "sell" ratings for Antibe Therapeutics in the last year. There are currently 1 buy rating for the stock. The consensus among Wall Street equities research analysts is that investors should "buy" ATBPF shares.
View ATBPF analyst ratings
or view top-rated stocks.

How have ATBPF shares performed in 2023?

Antibe Therapeutics' stock was trading at $0.3230 at the beginning of the year. Since then, ATBPF stock has increased by 10.9% and is now trading at $0.3583.
View the best growth stocks for 2023 here
.

Are investors shorting Antibe Therapeutics?

Antibe Therapeutics saw a decline in short interest in September. As of September 15th, there was short interest totaling 6,900 shares, a decline of 76.4% from the August 31st total of 29,200 shares. Based on an average daily volume of 27,000 shares, the days-to-cover ratio is currently 0.3 days.
View Antibe Therapeutics' Short Interest
.

When is Antibe Therapeutics' next earnings date?

The company is scheduled to release its next quarterly earnings announcement on Monday, November 13th 2023.
View our ATBPF earnings forecast
.

How were Antibe Therapeutics' earnings last quarter?

Antibe Therapeutics Inc. (OTCMKTS:ATBPF) posted its quarterly earnings data on Monday, August, 14th. The company reported ($0.08) earnings per share (EPS) for the quarter, missing the consensus estimate of ($0.07) by $0.01.

What is Antibe Therapeutics' stock symbol?

Antibe Therapeutics trades on the OTCMKTS under the ticker symbol "ATBPF."

How do I buy shares of Antibe Therapeutics?

Shares of ATBPF stock can be purchased through any online brokerage account. Popular online brokerages with access to the U.S. stock market include WeBull, Vanguard Brokerage Services, TD Ameritrade, E*TRADE, Robinhood, Fidelity, and Charles Schwab.
Compare Top Brokerages Here.

What is Antibe Therapeutics' stock price today?

One share of ATBPF stock can currently be purchased for approximately $0.36.

How much money does Antibe Therapeutics make?

Antibe Therapeutics (OTCMKTS:ATBPF) has a market capitalization of $18.86 million and generates $7.67 million in revenue each year. The company earns $-14,730,000.00 in net income (profit) each year or ($0.27) on an earnings per share basis.

How can I contact Antibe Therapeutics?

Antibe Therapeutics' mailing address is 15 PRINCE ARTHUR AVENUE, TORONTO A6, M5R 1B2. The official website for the company is www.antibethera.com. The company can be reached via phone at (416) 922-3460 or via email at christina@antibethera.com.

This page (OTCMKTS:ATBPF) was last updated on 10/2/2023 by MarketBeat.com Staff

My Account -